{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:57:14Z","timestamp":1769741834819,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Helsinn Healthcare SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40257-022-00687-y","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T11:03:09Z","timestamp":1652180589000},"page":"561-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data"],"prefix":"10.1007","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct00168064","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00535470","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christiane","family":"Querfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia J.","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"687_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:30\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdy133.","journal-title":"Ann Oncol"},{"key":"687_CR2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1172\/JCI24826","volume":"115","author":"EJ Kim","year":"2005","unstructured":"Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115:798\u2013812. https:\/\/doi.org\/10.1172\/JCI24826 (Erratum in: J Clin Invest. 2007;117:836).","journal-title":"J Clin Invest"},{"key":"687_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2017. Eur J Cancer. 2017;77:57\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.027.","journal-title":"Eur J Cancer"},{"key":"687_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjd.17240","volume":"180","author":"D Gilson","year":"2019","unstructured":"Gilson D, Whittaker SJ, Child FJ, Scarisbrick JJ, Illidge TM, Parry EJ, et al. British association of dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019;180:496\u2013526. https:\/\/doi.org\/10.1111\/bjd.17240.","journal-title":"Br J Dermatol"},{"key":"687_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines (NCCN Guidelines\u00ae) Primary cutaneous lymphomas. Version 2.2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf. Accessed 10 Nov 2021."},{"key":"687_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3949\/ccjm.26.3.144","volume":"26","author":"JR Haserick","year":"1959","unstructured":"Haserick JR, Richardson JH, Grant DJ. Remission of lesions in mycosis fungoides following topical application of nitrogen mustard: a case report. Cleve Clin J Med. 1959;26:144\u20137.","journal-title":"Cleve Clin J Med"},{"key":"687_CR7","unstructured":"Valchlor (mechlorethamine) [prescribing information]. Iselin, NJ: Helsinn Therapeutics (U.S.), Inc.; 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202317s009lbl.pdf. Accessed 10 Nov 2021."},{"key":"687_CR8","unstructured":"Ledaga [prescribing information]. Jerusalem, Israel: Rafa Laboratories Ltd.; 2020. https:\/\/mohpublic.z6.web.core.windows.net\/IsraelDrugs\/Rishum_17_462433720.pdf. Accessed 10 Nov 2021."},{"key":"687_CR9","unstructured":"Ledaga [summary of product characteristics]. Dublin, Ireland: Helsinn Birex Pharmaceuticals Ltd.; 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ledaga-epar-product-information_en.pdf. Accessed 10 Nov 2021."},{"key":"687_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100069","volume":"2","author":"YT Chang","year":"2021","unstructured":"Chang YT, Ignatova D, Hoetzenecker W, Pascolo S, Fassnacht C, Guenova E. Increased chlormethine-induced DNA double-stranded breaks in malignant T cells from mycosis fungoides skin lesions. JID Innov. 2021;2: 100069. https:\/\/doi.org\/10.1016\/j.xjidi.2021.100069.","journal-title":"JID Innov."},{"key":"687_CR11","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jid.2020.12.009","volume":"141","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Geskin LJ, Kim EJ, Scarisbrick JJ, Quaglino P, Papadavid E, et al. Lack of systemic absorption of topical mechlorethamine gel in patients with mycosis fungoides cutaneous T-cell lymphoma. J Invest Dermatol. 2021;141:1601-1604.e2. https:\/\/doi.org\/10.1016\/j.jid.2020.12.009.","journal-title":"J Invest Dermatol"},{"key":"687_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","volume":"149","author":"SR Lessin","year":"2013","unstructured":"Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149:25\u201332. https:\/\/doi.org\/10.1001\/2013.jamadermatol.541.","journal-title":"JAMA Dermatol"},{"key":"687_CR13","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29:2598\u2013607. https:\/\/doi.org\/10.1200\/JCO.2010.32.0630.","journal-title":"J Clin Oncol"},{"key":"687_CR14","doi-asserted-by":"publisher","DOI":"10.1159\/000516138","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Scarisbrick JJ, Assaf C, Guenova E, Bagot M, Ortiz-Romero PL, et al. Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine\/mechlorethamine gel in patients with stage IA\u2013IIA mycosis fungoides. Dermatology. 2021. https:\/\/doi.org\/10.1159\/000516138.","journal-title":"Dermatology"},{"key":"687_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.896","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Kim YH, Guitart J, Scarisbrick J, Quaglino P. Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: a phase 2 extension study. J Am Acad Dermatol. 2021. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.896.","journal-title":"J Am Acad Dermatol"},{"key":"687_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archderm.139.2.165","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139:165\u201373. https:\/\/doi.org\/10.1001\/archderm.139.2.165.","journal-title":"Arch Dermatol"},{"key":"687_CR17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1586\/17512433.2014.944500","volume":"7","author":"R Talpur","year":"2014","unstructured":"Talpur R, Venkatarajan S, Duvic M. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. Expert Rev Clin Pharmacol. 2014;7:591\u20137. https:\/\/doi.org\/10.1586\/17512433.2014.944500.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"687_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","volume":"22","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, et al. The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021;22:407\u201314. https:\/\/doi.org\/10.1007\/s40257-021-00591-x.","journal-title":"Am J Clin Dermatol"},{"key":"687_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1967266","author":"H Prag Naveh","year":"2021","unstructured":"Prag Naveh H, Amitay-Laish I, Zidan O, Leshem YA, Sherman S, Noyman Y, et al. Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects. J Dermatolog Treat. 2021. https:\/\/doi.org\/10.1080\/09546634.2021.1967266.","journal-title":"J Dermatolog Treat"},{"key":"687_CR20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s13555-021-00539-3","volume":"11","author":"LJ Geskin","year":"2021","unstructured":"Geskin LJ, Bagot M, Hodak E, Kim EJ. Chlormethine gel for the treatment of skin lesions in all stages of mycosis fungoides cutaneous T-cell lymphoma: a narrative review and international experience. Dermatol Ther (Heidelb). 2021;11:1085\u2013106. https:\/\/doi.org\/10.1007\/s13555-021-00539-3.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"687_CR21","unstructured":"Klucel\u2122 hydroxypropylcellulose. Physical and chemical properties. Ashland Inc.; 2017. https:\/\/www.ashland.com\/file_source\/Ashland\/Product\/Documents\/Pharmaceutical\/PC_11229_Klucel_HPC.pdf. Accessed 10 Nov 2021."},{"key":"687_CR22","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1016\/j.jid.2021.08.137","volume":"141","author":"C Giuliano","year":"2021","unstructured":"Giuliano C, Frizzarin S, Beuttel C, Powell K, Alonzi A, Stimamiglio V, et al. Percutaneous absorption of chlormethine gel in human skin: in vitro permeation testing. J Invest Dermatol. 2021;141:S171 (Abstract 134).","journal-title":"J Invest Dermatol"},{"key":"687_CR23","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/ddg.14462","volume":"19","author":"U Wehkamp","year":"2021","unstructured":"Wehkamp U, Jost M, Gosmann J, Grote U, Bernard M, Stadler R. Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers. J Dtsch Dermatol Ges. 2021;19:1057\u20139. https:\/\/doi.org\/10.1111\/ddg.14462.","journal-title":"J Dtsch Dermatol Ges"},{"key":"687_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000453265","volume":"171","author":"WJ Pichler","year":"2016","unstructured":"Pichler WJ, Hausmann O. Classification of drug hypersensitivity into allergic, p-i, and pseudo-allergic forms. Int Arch Allergy Immunol. 2016;171:166\u201379. https:\/\/doi.org\/10.1159\/000453265.","journal-title":"Int Arch Allergy Immunol"},{"key":"687_CR25","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jdcr.2020.05.031","volume":"6","author":"ES Gilmore","year":"2020","unstructured":"Gilmore ES, Alexander-Savino CV, Chung CG, Poligone B. Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis. JAAD Case Rep. 2020;6:878\u201381. https:\/\/doi.org\/10.1016\/j.jdcr.2020.05.031.","journal-title":"JAAD Case Rep."},{"key":"687_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00681-6","author":"CV Alexander-Savino","year":"2022","unstructured":"Alexander-Savino CV, Chung CG, Gilmore ES, Carroll SM, Poligone B. Randomized Mechlorethamine\/Chlormethine Induced Dermatitis Assessment Study (MIDAS) establishes benefit of topical triamcinolone 0.1% ointment cotreatment in mycosis fungoides. Dermatol Ther. 2022. https:\/\/doi.org\/10.1007\/s13555-022-00681-6.","journal-title":"Dermatol Ther"},{"key":"687_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s11096-016-0404-4","volume":"39","author":"F Dugre","year":"2017","unstructured":"Dugre F, Lefebure A, Martelli S, Pin M, Maubec E, Arnaud F. Chlormethine gel: effectiveness and tolerance to treat mycosis fungoides. Int J Clin Pharm. 2017;39:252. https:\/\/doi.org\/10.1007\/s11096-016-0404-4 (Abstract DI006).","journal-title":"Int J Clin Pharm"},{"key":"687_CR28","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1007\/s12325-021-01721-x","volume":"38","author":"K Lampadaki","year":"2021","unstructured":"Lampadaki K, Koumourtzis M, Karagianni F, Marinos L, Papadavid E. Chlormethine gel in combination with other therapies in the treatment of patients with mycosis fungoides cutaneous T cell lymphoma: three case reports. Adv Ther. 2021;38:3455\u201364. https:\/\/doi.org\/10.1007\/s12325-021-01721-x.","journal-title":"Adv Ther"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00687-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00687-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00687-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:52:38Z","timestamp":1659113558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00687-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00687-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"17 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Helsinn Healthcare SA was involved in reviewing of the manuscript according to Good Publication Practices (). Writing and editorial assistance was funded by Helsinn Healthcare SA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C. Querfeld: Research grant: Celgene; clinical investigator: Helsinn, Celgene, Trillium, miRagen, Bioniz, Kyowa Kirin; advisory board: Helsinn, miRagen, Bioniz, Almirall, Trillium, Kyowa Kirin, Stemline Therapeutics. J.J. Scarisbrick: Consultancy: Takeda, Helsinn, Recordati, 4SC, Kyowa, Mallinckrodt, miRagen; research grant: Kyowa. C. Assaf: Advisory board: 4SC, Takeda, Helsinn, Innate Pharma, Recordati Rare Diseases, Kyowa. Y.H. Kim: Steering committee and research funding: Eisai; research funding: Forty Seven; advisory board member: Seattle Genetics; steering committee member, advisory board, and research funding: Kyowa Hakko Kirin; research funding: Portola, Horizon; research funding: Soligenix; steering committee, advisory board, research funding: Innate; research funding: Elorac; advisory board and research funding: Galderma; steering committee and research funding: Corvus; research funding Trillium. J. Guitart: Research support: Galderma, Soligenix; scientific advisory board: Kyowa Kirin. P. Quaglino: Advisory board: 4SC, Takeda, Actelion, Innate Pharma, Helsinn, Recordati Rare Diseases, Kyowa, Therakos. E. Hodak: Scientific advisory board: Actelion, Helsinn, Recordati Rare Diseases, Takeda; speakers\u2019 bureau: Helsinn, Rafa, Takeda.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocols were approved by institutional review boards of the participating centers and complied with Good Clinical Practice guidelines and the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Concept and design: CQ, JJS, CA, YHK, JG, PQ, EH. Drafting of the article or critical revision of the article for important intellectual content: CQ, JJS, CA, YHK, JG, PQ, EH. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}